A critical healthcare crisis is unfolding in South Africa as the consequences of former US President Donald Trump’s executive order, signed immediately following his inauguration, continue to reverberate across the nation’s HIV/AIDS programs. The sudden freezing of US aid commitments has created a $400 million annual funding gap, representing approximately one-fifth of South Africa’s total HIV program budget.
South Africa, bearing the world’s highest HIV burden with 13% of its population living with the virus, now faces severe service disruptions despite government efforts to mitigate the impact. The South African government managed to allocate just $46 million—a mere 11.5% of the lost funding—while a temporary “bridge plan” of $115 million from the US President’s Emergency Fund for AIDS Relief (Pepfar) will only sustain operations until March.
The funding cuts have particularly affected vital “last-mile” services, according to Professor Linda-Gail Bekker, head of the Desmond Tutu Health Foundation. These include mobile clinics that reach vulnerable populations in high-risk areas like Philippi, one of Cape Town’s most dangerous townships. These clinics provide essential services to those uncomfortable with government facilities, offering innovative prevention methods like Cabotegravir (CAB-LA) and the promising twice-yearly injection Lenecapavir.
Young South Africans express grave concerns about service accessibility. Esethu, 28, receiving her second CAB-LA injection, emphasized the importance of mobile clinics: “They are very important for young people because when you go to the government clinics, you get people that are your mother’s age, so you can’t open up to them.”
Health Minister Dr. Aaron Motsoaledi acknowledges the challenge, hoping for increased HIV funding in the next budget while pursuing alternative donors. Through the Global Fund, South Africa has secured 900,000 doses of Lenacapavir for 450,000 people, scheduled for distribution within months. However, researchers warn this remains insufficient to address the 180,000 new infections recorded last year.
Experts fear the cuts will reverse decades of progress. Professor Helen Rees of Wits RHI notes the profound impact of sudden service reductions: “If you stop testing, if you stop giving prevention, and if you are unable to sustain treatment, you’re inevitably going to get more cases.” Ironically, the very data collection needed to measure the crisis impact has been compromised by funding limitations.
The situation highlights global health interdependence, as research advancements from South Africa—a global leader in HIV studies partly due to previous US funding—have worldwide implications. With the US adopting an “America First Global Health Strategy” and shifting to bilateral agreements with countries like Kenya, Malawi, and Nigeria, the future of international health cooperation remains uncertain.
